The North American Menopause Society’s 2021 Annual Meeting has officially begun
Check in throughout the week for the latest coverage from the North American Menopause Society’s (NAMS) Annual Meeting, which is being held Sept. 22-25 in Washington, D.C.
The meeting will continue this week until September 25, 2021. To register or find get more information, visit menopause.org.
As the leading medical conference dedicated to promoting women’s health at midlife and beyond, NAMS’ 2021 Annual Meeting offers comprehensive and exciting updates on the most relevant issues relating to menopause and midlife women’s health.
This year’s Translational Science Symposium will focus on the biology and practice of wellness, during which attendees can expect to gain a novel, foundational framework for the concept of wellness and learn behavioral approaches to promote healthy aging in clinical practice.
The meeting is supported by The National Institute on Aging of the National Institutes of Health under Award Number R13AG069384.
Follow along with Contemporary OB/GYN® as we cover critical topics in midlife women’s health, including:
- Virtual menopause care;
- Cardiovascular disease;
- Abnormal uterine bleeding;
- Vasomotor symptom management;
- Cervical cancer; and
- Bone health evaluation and prevention.
Throughout the meeting, attendees will have the opportunity to earn 29 high-quality continuing education credit hours.
For registrants unable to attend the meeting in person, content also will be available on demand. The on-demand platform will provide registrants with a digital library of presentations from the 2021 NAMS Annual Meeting, Pre-Meeting Symposium, and Menopause 101 Course.
S3E20: Brooke Faught, NP on sexual health, trauma-informed care, and the perks of meeting in-person
December 3rd 2021In this episode of Pap Talk, we took you with us to the North American Menopause Society's recent Annual Meeting. Sexual health specialist Michael Krychman, MD, sat down with Brooke Faught, NP, to learn more about her work at the Women's Institute for Sexual Health, her role on the NAMS Planning Committee, and her tips for talking trauma with patients.
Listen
Elinzanetant's efficacy for vasomotor symptoms confirmed in phase 3 trial
March 19th 2024Bayer's OASIS 3 trial affirmsed the safety and efficacy of elinzanetant in reducing moderate to severe vasomotor symptoms, bolstering confidence in its potential as a non-hormonal solution for menopause-related issues.
Read More
